Alvogen Launches Inflectra In Europe With Hospira, Inc.
2/13/2014 8:49:32 AM
PINEBROOK, N.J.--(BUSINESS WIRE)--Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra™ (Infliximab) into Central and Eastern Europe. InflectraTM, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis. Alvogen and Hospira formed a strategic partnership in 2011 to provide the highest quality products and services for customers and patients throughout Central and Eastern Europe (CEE). This alliance enables us to provide increased access to the newest biosimilar drugs with state-of-the-art technology.
Help employers find you! Check out all the jobs and post your resume.